trending Market Intelligence /marketintelligence/en/news-insights/trending/pidHEjDLlFp7eukZ-gX-4Q2 content esgSubNav
In This List

India's Pfizer to buy AstraZeneca's gastrointestinal drug brand

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Blog

Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise


India's Pfizer to buy AstraZeneca's gastrointestinal drug brand

Pfizer Ltd. agreed to acquire the Neksium brand in India from AstraZeneca PLC's Swedish unit AstraZeneca AB for 750 million Indian rupees.

India-based Pfizer said the acquisition of the brand will complement its existing product portfolio in the gastrointestinal therapeutic area.

The closing of the transaction is subject to customary closing conditions.